PDS Biotechnology Reports Financial Results for the First Quarter 2020 and Provides Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
PDS Biotechnology (PDSB) Misses Q1 EPS by 24c
May 13, 2020 6:01 AM EDTPDS Biotechnology (NASDAQ: PDSB) reported Q1 EPS of ($0.39), $0.24 worse than the analyst estimate of ($0.15).
First Quarter 2020 and Recent Business Highlights
Initiated novel vaccine development programs for COVID-19 and universal influenza;Announced pre-clinical collaboration with Farmacore Biotechnology for tuberculosis;Delayed initiation of Phase 2 VERSATILE-002 trial for PDS0101 in recurrent/metastatic head and neck cancer due to the global COVID-19 pandemic;Secured the U.S. composition of matter patent for the Versamune® platform;Expanded... More